{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:07:17Z","timestamp":1776294437113,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13318-024-00925-0","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:02:18Z","timestamp":1730455338000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Loss-of-Function ATP Binding Cassette Subfamily G Member 2 Polymorphism ABCG2 c.421C>A Reduces Lamotrigine Trough Concentrations in Adults with Epilepsy"],"prefix":"10.1007","volume":"50","author":[{"given":"Nada","family":"Bo\u017eina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva Klarica","family":"Domjanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana \u0160u\u0161ak","family":"Spori\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Ganoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Lovri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-1194","authenticated-orcid":false,"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"4","key":"925_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/FPC.0000000000000397","volume":"30","author":"T Mitra-Ghosh","year":"2020","unstructured":"Mitra-Ghosh T, Callisto SP, Lamba JK, Remmel RP, Birnbaum AK, Barbarino JM, et al. PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2020;30(4):81\u201390. https:\/\/doi.org\/10.1097\/FPC.0000000000000397.","journal-title":"Pharmacogenet Genom"},{"key":"925_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-319-32909-3_11","volume-title":"Antiepileptic drug interactions. A clinical guide","author":"PN Patsalos","year":"2016","unstructured":"Patsalos PN. Antiepileptic drug interactions. A clinical guide. 3rd ed. London: Springer; 2016. p. 55\u20139.","edition":"3"},{"issue":"2","key":"925_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/fcp.12958","volume":"38","author":"I \u0160u\u0161ak Spori\u0161","year":"2024","unstructured":"\u0160u\u0161ak Spori\u0161 I, Bo\u017eina N, Klarica Domjanovi\u0107 I, Spori\u0161 D, Ba\u0161i\u0107 S, et al. Breast cancer resistance protein polymorphism ABCG2 c.421C>A (rs2231142) moderates the effect of valproate on lamotrigine trough concentrations in adults with epilepsy. Fundam Clin Pharmacol. 2024;38(2):351\u201368. https:\/\/doi.org\/10.1111\/fcp.12958.","journal-title":"Fundam Clin Pharmacol"},{"key":"925_CR4","unstructured":"Gerifer N. WeightIt: Weighting for covariate balance in observational studies. R package version 1.2.1, https:\/\/ngreifer.github.io\/WeightIt\/."},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/jrsm.1331","volume":"10","author":"K Papadimitropoulou","year":"2019","unstructured":"Papadimitropoulou K, Stijnen T, Dekkers OM, le Cessie S. One-stage random effects meta-analysis using linear mixed models for aggregate continuous outcome data. Res Synth Methods. 2019;10:360\u201375. https:\/\/doi.org\/10.1002\/jrsm.1331.","journal-title":"Res Synth Methods"},{"key":"925_CR6","unstructured":"Goodrich B, Gabry J, Ali I, Brilleman S. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3, 2022, https:\/\/mc-stan.org\/rstanarm\/"},{"issue":"4","key":"925_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"key":"925_CR8","doi-asserted-by":"publisher","unstructured":"Heine D. The episensr package: basic sensitivity analysis of epidemiological results. 2021. https:\/\/doi.org\/10.5281\/zenodo.4554553, R package version 1.1.0, https:\/\/dhaine.github.io\/episensr\/","DOI":"10.5281\/zenodo.4554553"},{"issue":"11","key":"925_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for ABCG2. Pharmacogenet Genom. 2017;27(11):420\u20137. https:\/\/doi.org\/10.1097\/FPC.0000000000000305.","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"925_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1528-1157.1999.tb01990.x","volume":"40","author":"FP Meyer","year":"1999","unstructured":"Meyer FP, Banditt P, Schubert A, Schoche J. Lamotrigine concentrations in human serum, brain tissue, and tumor tissue. Epilepsia. 1999;40(1):68\u201373. https:\/\/doi.org\/10.1111\/j.1528-1157.1999.tb01990.x.","journal-title":"Epilepsia"},{"key":"925_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020591","author":"W Loscher","year":"2020","unstructured":"Loscher W, Friedman A. Structural, molecular and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both? Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21020591.","journal-title":"Int J Mol Sci"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00925-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00925-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00925-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:49:23Z","timestamp":1738824563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00925-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00925-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"17 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies presented in this report received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors have any conflict of interest to declare. The authors declare no support from any organization for the submitted work, no other financial relationships with any organizations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies were conceived and designed by Nada Bo\u017eina, Iva Klarica Domjanovi\u0107, Ivana \u0160u\u0161ak Spori\u0161 and Vladimir Trkulja. Ivana \u0160u\u0161ak Spori\u0161 executed and supervised recruitment and management of most of the included patients. Lana Ganoci performed genetic analysis, Mila Lovri\u0107 pefromed lamotrigine measurements, and both were supervised by Nada Bo\u017eina. Data were collected and assembled by Iva Klarica Domjanovi\u0107, Ivana \u0160u\u0161ak Spori\u0161, Lana Ganoci and Mila Lovri\u0107. The present analysis was performed by Vladimir Trkulja who drafted the manuscript. Data were interpreted by Nada Bo\u017eina and Vladimir Trkulja. All co-authors provided final approval of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Both studies presented in this report were approved by the Institutional Ethics Committee (Study 1 \u2013 approval class: 8.1.-14\/78-2, registration number: 02\/21\/JG, issued October 7, 2015; Study 2 \u2013 approval class: 8.1.-19\/12-2, registration number: 02\/21 AG, issued November 29, 2018).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Only patients who signed a written informed consent for (1) genotyping for the pharmacogenes of interest and (2) publication of (anonymized) data for scientific purposes were included in the studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data\/datasets generated for the present analysis are available from the corresponding author upon a reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Codes used to generate frequentist (SAS for Windows 9.4) and Bayes estimates (R package rstanarm) are available from the corresponding author upon request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}